Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | DPYD | Q12882 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16586691 | 1.00 | GPR84 (0.43) | GPR84DPYDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16585678 | 0.92 | GPR84 (0.46) | GPR84DPYDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL31045506 | 0.91 | DPYD (0.46) | GPR84DPYDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1050748 | 0.86 | DPYD (0.47) | GPR84DPYDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1890981 | 0.80 | DPYD (0.50) | DPYDTSHRKDM4ELMNAMAPT | |
| SCHEMBL3485393 | 0.77 | DPYD (0.53) | DPYDTSHRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL1586447 | 0.74 | DPYD (0.40) | GPR84DPYDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1586445 | 0.74 | DPYD (0.40) | GPR84DPYDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL31045516 | 0.74 | DPYD (0.54) | DPYDTSHRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL22748451 | 0.67 | FFAR1 (0.42) | GPR84CYP3A4CYP2C9CYP2C19FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10285939-B2 | Means and methods for ocular drug delivery | EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) | 2019-05-14 | — | — | US | disclosed |
| EP-3057572-B1 | MEANS AND METHODS FOR OCULAR DRUG DELIVERY | EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) | 2018-01-31 | — | — | EP | disclosed |
| US-20160346203-A1 | MEANS AND METHODS FOR OCULAR DRUG DELIVERY | EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) | 2016-12-01 | — | — | US | disclosed |
| EP-3057572-A1 | MEANS AND METHODS FOR OCULAR DRUG DELIVERY | Rijksuniversiteit Groningen (NL) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015041520-A1 | MEANS AND METHODS FOR OCULAR DRUG DELIVERY | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285939-B2 | Means and methods for ocular drug delivery | UACA, PDE6C, CRYAA | GPR84 1696/4885DPYD 3498/4885CYP3A4 4698/4885 |
| US-20160346203-A1 | MEANS AND METHODS FOR OCULAR DRUG DELIVERY | UACA, PDE6C, CRYAA | GPR84 1696/4885DPYD 3498/4885CYP3A4 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.